A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with ...
3d
Clinical Trials Arena on MSNCorcept’s Phase III trial of ovarian cancer therapy shows PFS improvementThe trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...
3d
Zacks.com on MSNCORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study GoalThe ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...
It wasn’t like any other birthday for Rosella Nix, a resident at the Wesley House Assisted Living Center in Gilmer.
In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients treated with nab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results